Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138888301> ?p ?o ?g. }
- W2138888301 endingPage "1542" @default.
- W2138888301 startingPage "1533" @default.
- W2138888301 abstract "Background Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa. Methods We pooled data from six double-blind, randomised, placebo-controlled trials (undertaken one each in Tanzania, Mozambique, and Gabon, and three in Ghana) that assessed the efficacy of IPTi with sulfadoxine-pyrimethamine. In all trials, IPTi or placebo was given to infants at the time of routine vaccinations delivered by WHO's Expanded Program on Immunization. Data from the trials for incidence of clinical malaria, risk of anaemia (packed-cell volume <25% or haemoglobin <80 g/L), and incidence of hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome definitions and time periods. Analysis was by modified intention to treat, including all infants who received at least one dose of IPTi or placebo. Findings The six trials provided data for 7930 infants (IPTi, n=3958; placebo, n=3972). IPTi had a protective efficacy of 30·3% (95% CI 19·8–39·4, p<0·0001) against clinical malaria, 21·3% (8·2–32·5, p=0·002) against the risk of anaemia, 38·1% (12·5–56·2, p=0·007) against hospital admissions associated with malaria parasitaemia, and 22·9% (10·0–34·0, p=0·001) against all-cause hospital admissions. There were 56 deaths in the IPTi group compared with 53 in the placebo group (rate ratio 1·05, 95% CI 0·72–1·54, p=0·79). One death, judged as possibly related to IPTi because it occurred 19 days after a treatment dose, was subsequently attributed to probable sepsis. Four of 676 non-fatal hospital admissions in the IPTi group were deemed related to study treatment compared with five of 860 in the placebo group. None of three serious dermatological adverse events in the IPTi group were judged related to study treatment compared with one of 13 in the placebo group. Interpretation IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a useful contribution to malaria control. Funding Bill & Melinda Gates Foundation." @default.
- W2138888301 created "2016-06-24" @default.
- W2138888301 creator A5000784501 @default.
- W2138888301 creator A5007907013 @default.
- W2138888301 creator A5010966506 @default.
- W2138888301 creator A5015285519 @default.
- W2138888301 creator A5018692963 @default.
- W2138888301 creator A5018831973 @default.
- W2138888301 creator A5019096760 @default.
- W2138888301 creator A5026726987 @default.
- W2138888301 creator A5027270405 @default.
- W2138888301 creator A5042765093 @default.
- W2138888301 creator A5043369631 @default.
- W2138888301 creator A5043650852 @default.
- W2138888301 creator A5046963420 @default.
- W2138888301 creator A5053562358 @default.
- W2138888301 creator A5055698202 @default.
- W2138888301 creator A5058335415 @default.
- W2138888301 creator A5067543752 @default.
- W2138888301 creator A5069058134 @default.
- W2138888301 creator A5069178443 @default.
- W2138888301 creator A5069887853 @default.
- W2138888301 creator A5073562106 @default.
- W2138888301 creator A5078792522 @default.
- W2138888301 creator A5082622465 @default.
- W2138888301 creator A5082788819 @default.
- W2138888301 creator A5084937607 @default.
- W2138888301 creator A5085483706 @default.
- W2138888301 creator A5087477162 @default.
- W2138888301 creator A5087605771 @default.
- W2138888301 creator A5087875632 @default.
- W2138888301 creator A5089721938 @default.
- W2138888301 creator A5090444000 @default.
- W2138888301 creator A5091869484 @default.
- W2138888301 date "2009-10-01" @default.
- W2138888301 modified "2023-10-16" @default.
- W2138888301 title "Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials" @default.
- W2138888301 cites W1635729316 @default.
- W2138888301 cites W1929978043 @default.
- W2138888301 cites W1980658344 @default.
- W2138888301 cites W1995790157 @default.
- W2138888301 cites W2022925846 @default.
- W2138888301 cites W2026689559 @default.
- W2138888301 cites W2036179744 @default.
- W2138888301 cites W2039018737 @default.
- W2138888301 cites W2040626202 @default.
- W2138888301 cites W2045769685 @default.
- W2138888301 cites W2058851764 @default.
- W2138888301 cites W2066304169 @default.
- W2138888301 cites W2082271668 @default.
- W2138888301 cites W2094710221 @default.
- W2138888301 cites W2096883543 @default.
- W2138888301 cites W2097667956 @default.
- W2138888301 cites W2099432941 @default.
- W2138888301 cites W2101852092 @default.
- W2138888301 cites W2102280420 @default.
- W2138888301 cites W2104697202 @default.
- W2138888301 cites W2106087767 @default.
- W2138888301 cites W2108075232 @default.
- W2138888301 cites W2112669742 @default.
- W2138888301 cites W2114022593 @default.
- W2138888301 cites W2114186504 @default.
- W2138888301 cites W2117147524 @default.
- W2138888301 cites W2117826271 @default.
- W2138888301 cites W2121762116 @default.
- W2138888301 cites W2122230112 @default.
- W2138888301 cites W2124971883 @default.
- W2138888301 cites W2125435699 @default.
- W2138888301 cites W2137774293 @default.
- W2138888301 cites W2139662973 @default.
- W2138888301 cites W2142275831 @default.
- W2138888301 cites W2142751154 @default.
- W2138888301 cites W2146741446 @default.
- W2138888301 cites W2147502026 @default.
- W2138888301 cites W2147895892 @default.
- W2138888301 cites W2149001398 @default.
- W2138888301 cites W2149136110 @default.
- W2138888301 cites W2149676602 @default.
- W2138888301 cites W2153526195 @default.
- W2138888301 cites W2163934961 @default.
- W2138888301 cites W2169649862 @default.
- W2138888301 cites W2414725590 @default.
- W2138888301 doi "https://doi.org/10.1016/s0140-6736(09)61258-7" @default.
- W2138888301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19765816" @default.
- W2138888301 hasPublicationYear "2009" @default.
- W2138888301 type Work @default.
- W2138888301 sameAs 2138888301 @default.
- W2138888301 citedByCount "203" @default.
- W2138888301 countsByYear W21388883012012 @default.
- W2138888301 countsByYear W21388883012013 @default.
- W2138888301 countsByYear W21388883012014 @default.
- W2138888301 countsByYear W21388883012015 @default.
- W2138888301 countsByYear W21388883012016 @default.
- W2138888301 countsByYear W21388883012017 @default.
- W2138888301 countsByYear W21388883012018 @default.
- W2138888301 countsByYear W21388883012019 @default.
- W2138888301 countsByYear W21388883012020 @default.
- W2138888301 countsByYear W21388883012021 @default.